Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Condition: Metastatic Hormone-Sensitive Prostate Cancer Interventions: Drug: docetaxel 50mg/m2; Drug: docetaxel 75mg/m2 Sponsor: Peng Wang Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Docetaxel | Hormones | Prostate Cancer | Research | Taxotere | Toxicology